SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as a community-driven project that is rallying behind the development of its ticker and charting integration, with supporters emphasizing its focus on organic growth and transparent tokenomics. The community is actively using social platforms to boost visibility and volume, framing the project as a long-term alternative to the volatility of other meme coin sectors.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as investors debate the impact of agentic AI competition against the company's strong fundamentals and established enterprise role. While the community remains polarized by recent volatility and technical support levels, many are focused on the upcoming product showcase as a potential catalyst to shift the narrative and challenge short interest.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is facing significant selling pressure amid a broader software sector rotation, fueled by a UBS downgrade and market-wide concerns that AI disruption may commoditize traditional IT enterprise platforms. While the community remains deeply divided between those viewing the decline as a rare value opportunity for a long-term enterprise staple and those warning of a structural breakdown in SaaS valuation models, heavy volume and RSI levels have many traders actively debating whether a capitulation bottom is finally forming.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is experiencing heightened volatility and intense social media chatter following an unprecedented endorsement by President Trump, which has sparked a heated debate between retail bulls betting on a short squeeze and institutional skeptics questioning the company's valuation compared to rivals like Anthropic. The stock is currently at the center of a liquidity battle as traders weigh the impact of potential new government defense contracts against critical bearish sentiment regarding the software sector's long-term outlook.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon is seeing intense market interest and a sharp price surge driven by unconfirmed headlines regarding a potential $12 billion acquisition bid by Sun Pharma. While the community is actively debating the credibility of the reports and the impact of the company's significant debt load, the stock remains a focal point for M&A speculators and those tracking a potential breakout.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently generating significant market conversation centered on speculative buzz regarding a potential ETF filing, which supporters argue highlights the meme coin's growing institutional legitimacy and cultural staying power. While some community members remain wary of volatility and broader sector instability, others are leveraging this institutional interest to fuel discussions about upcoming price rallies and long-term holding strategies.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake is facing intense volatility as the market reacts to a strong earnings report and AI growth metrics with a sharp sell-off, highlighting concerns over high valuations and competitive pressure from emerging AI models. Investors are currently torn between the company's solid revenue growth and the broader sector-wide repricing of high-multiple SaaS stocks amid fears of AI-driven disruption.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending due to a major multi-year compute deal with Anthropic and an expanded capacity agreement with Meta, which have energized investor interest in the stock. While these partnerships highlight CoreWeave's role as a critical AI infrastructure provider, the community is actively debating the impact of a concurrent debt offering, weighing the massive growth potential against the implications of ongoing corporate dilution.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals is capturing significant community attention as investors weigh its deep discount to cash-on-hand against the high-stakes potential of its lead candidate, azenosertib, with pivotal trial data expected soon. While some traders are bullish on institutional accumulation and the possibility of a buyout, others remain cautious, citing the company's high cash burn rate, recent strategic restructuring, and a history of volatility.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors react to a recent analyst upgrade and the company's decision to walk away from a potential Warner Bros. Discovery acquisition, with the community closely tracking its momentum toward the key $100 resistance level. Bullish sentiment is fueled by expectations of strong organic growth, while traders remain highly focused on upcoming earnings and potential technical breakouts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BHVN What are the chances do you all think FDA agrees to a path forward and will revist the approval of the drug that got CRLed by the last guy that left FDA? Many companies were mad, and BHVN wants a path forward. Could lift us back again.

StockTwits Web

Biohaven Pharmaceutical Holding Company Ltd

 What are the chances do you all think FDA agrees to a path forward and will revist the approval of the drug that got CRLed by the last guy that left FDA? Many companies were mad, and BHVN wants a path forward. Could lift us back again.

iShares Silver Trust

Altimmune Inc

Ondas Inc

Red Cat Holdings Inc

Rocket Lab USA Inc

Intuitive Machines Inc

Unusual Machines Inc

StockWarriorChief

@Timefortendies77 Correct my if I&#39;m wrong, but I don&#39;t believe the Prasad was the one who CRL&#39;d Biohaven. Wrong division. 
 
Biohaven has always planned to appeal and is actively appealing the CRL right now. It is a lengthy process, and one that is usually futile (think ~10% chance of success). 
 
However, like you stated, there seems to be a shift going on. Who knows where the odds are. I would still say probably on the lowish side; HOWEVER, analysts have completely written off this program. If this was to be a hit, it would have massive implications for the company and they would be able to fund their ambitious clinical without the need for dilution.  
 
There are so many catalysts coming up, just sit back and relax and let&#39;s hope for some good news to start flowing in. Cheers!

 Correct my if I'm wrong, but I don't believe the Prasad was the one who CRL'd Biohaven. Wrong division. 
 
Biohaven has always planned to appeal and is actively appealing the CRL right now. It is a lengthy process, and one that is usually futile (think ~10% chance of success). 
 
However, like you stated, there seems to be a shift going on. Who knows where the odds are. I would still say probably on the lowish side; HOWEVER, analysts have completely written off this program. If this was to be a hit, it would have massive implications for the company and they would be able to fund their ambitious clinical without the need for dilution.  
 
There are so many catalysts coming up, just sit back and relax and let's hope for some good news to start flowing in. Cheers!

SELLAS Life Sciences Group Inc

MoonLake Immunotherapeutics

@Freed_From_Desire true even without CRL being fixed (with all the analysts have written off) tons of potential. It is notable though that Biohaven CEO and Legislative Affairs met with Chief Counsel for FDA Mid-March. Normally meetings following CRL are with lower level investigators and reviewers not the CC for FDA. In terms of the review CDER was responsible for BHVN review originally. This center has experienced &quot;leadership instability,&quot; with multiple directors in a single year. Dr. Tracy Beth H was named Acting Director in late 2025. She replaced Dr. Richard P who briefly led the center after the resignation of Dr. George T. Point being new leadership is good.

 true even without CRL being fixed (with all the analysts have written off) tons of potential. It is notable though that Biohaven CEO and Legislative Affairs met with Chief Counsel for FDA Mid-March. Normally meetings following CRL are with lower level investigators and reviewers not the CC for FDA. In terms of the review CDER was responsible for BHVN review originally. This center has experienced "leadership instability," with multiple directors in a single year. Dr. Tracy Beth H was named Acting Director in late 2025. She replaced Dr. Richard P who briefly led the center after the resignation of Dr. George T. Point being new leadership is good.